Novo Nordisk’s Pipeline Ambitions Clash With Near-Term Revenue Fears as Analysts Flag 2027 Slowdown

Shares in Novo Nordisk have staged a sharp recovery from their late-March trough, climbing more than 26% to €38.81. That rally, however, masks an unsettling divergence between the stock’s recent momentum and the outlook painted by some analysts. Intron Health projects a 3% revenue contraction in 2027, warning that Wall Street has overestimated US sales of key drugs such as Ozempic and Rybelsus by roughly 8%. The firm sees multiple headwinds tightening around the Danish pharma giant, from cooling search interest in weight?loss injections to new administrative hurdles for patients if Medicare refuses to cover costs. With nearly 94% of net revenue tied to diabetes and obesity treatments, any stumble in that segment hits the entire top line.

Yet the bearish near?term thesis exists alongside a richly populated pipeline that could reshape the growth narrative. Novo Nordisk is advancing Amycretin, a dual GLP?1/amylin receptor agonist that combines two mechanisms in a single molecule. In a Phase?1b/2a trial, weekly subcutaneous injections delivered a 22% weight loss after 36 weeks. An oral formulation yielded a 13.1% reduction after 12 weeks of daily dosing. The company has now formally launched the AMAZE Phase?3 program, with the first study (AMAZE?1) already recruiting and measuring body?weight change at 84 weeks as its primary endpoint. A separate study, AMAZE?12, targets weight maintenance after initial loss — a commercially distinct and underexplored therapeutic goal.

Regulatory catalysts loom large on the calendar. Novo Nordisk notched six approvals and initiated more than ten clinical trials in the first quarter of 2026 alone. The FDA is expected to review the CagriSema combination — cagrilintide plus semaglutide — later this year. Larger Phase?3 data for CagriSema, including the REDEFINE?11 study, are due in the first half of 2027, and a higher?dose Phase?3 study is slated for the second half of 2026. A mechanistic trial of cagrilintide is also underway, probing how the drug affects food intake and hunger to inform the next generation of therapies.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The near?term headwinds, however, are not easily dismissed. Intron Health’s analyst Naresh Chouhan points to rising margin pressure and regulatory friction as patients face tighter eligibility checks. Google search trends suggest waning public enthusiasm for weight?loss injections in the US, where Novo Nordisk’s dependence on the obesity?diabetes axis is most acute. The 94% revenue concentration in that area leaves the group acutely exposed to any softening in demand or reimbursement.

Analyst opinion reflects the tension. Most experts currently rate the stock a hold, and Barclays recently reaffirmed a neutral stance. Despite the 26% bounce from the March low, the shares remain 13% lower on a year?to?date basis.

The bull case rests on a pipeline that could deliver three blockbuster pillars — Wegovy, CagriSema, and ultimately Amycretin — if the dual?receptor biology proves reliable at scale. Oral formulations and the potential for less frequent dosing open additional commercial avenues. But investors will have to navigate a period of revenue stagnation and regulatory uncertainty first. The first major Amycretin readout is expected in 2027, a year that could clarify whether Novo Nordisk’s near?term pain is merely a prelude to a much larger opportunity.

Ad

Novo Nordisk Stock: New Analysis - 20 May

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69383030 |